Details

Autor(en) / Beteiligte

• Pietrantonio, Filippo
• Biondani, Pamela
• Perrone, Federica
• Di Bartolomeo, Maria
• Pacifici, Monica
• Milione, Massimo
• Melotti, Flavia
• Maggi, Claudia
• Montemurro, Gabriella
• Bossi, Ilaria
• Mariani, Luigi
• de Braud, Filippo

Titel

TP53 Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon

Ist Teil von

• Oncology, 2014-01, Vol.86 (5-6), p.289-294

Ort / Verlag

Basel, Switzerland: S. Karger AG

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Background: Evidence for TP53 mutations as biomarker in colorectal cancer (CRC) is conflicting. Methods: We assessed TP53 mutations in 51 patients with advanced CRC enrolled into a phase II, randomised trial of first-line tegafur-uracil (UFT)/leucovorin (LV) plus irinotecan (n = 23) versus UFT/LV plus oxaliplatin (n = 28). Results: Non-functional TP53 mutations were found in 35% of patients. The response rate was not significantly different according to TP53 status. Progression-free and overall survival were longer in patients with TP53 mutations compared to those with wild-type TP53 (9 vs. 6.5 months, p = 0.0504, and 39.2 vs. 19.6 months, p = 0.0055, respectively). On multivariable analysis, TP53 mutation was independently associated with a decreased risk of death (hazard ratio 0.329, 95% CI 0.159-0.679; p = 0.0026). Treatment arm did not interact with TP53 in influencing outcomes. Conclusion:TP53 was not predictive of benefit from first-line irinotecan- or oxaliplatin-based chemotherapy. TP53 mutations may possibly be associated with a more indolent course of CRC after the diagnosis of metastatic disease.